Jenkoo (@Jenkoool) profile picture

AIM Investor

Joined February 2022
Photo by Jenkoo (@Jenkoool)Photo by Jenkoo (@Jenkoool)Photo by Jenkoo (@Jenkoool)Photo by Jenkoo (@Jenkoool)Photo by Jenkoo (@Jenkoool)Photo by Jenkoo (@Jenkoool)Photo by Jenkoo (@Jenkoool)Photo by Jenkoo (@Jenkoool)Photo by Jenkoo (@Jenkoool)Photo by Jenkoo (@Jenkoool)
Agree, I just doubt that current Gen1,2,3 would be suitable unless tailored to pass the bbb 👍🏻
1
1
202
Replying to @SeanDentBsc @avacta
I know the blood brain barrier could provide stiff challenge for Avacta. Unfortunately my dad is at the end of his 18month life expectancy suffering with a grade 4 glioblastoma. I was rather hoping there would be a trial for GB in truth. Sincerely hope it works for others sake ❤️
1
1
10
383
Replying to @tom_the_bomb__
Suprised me that some are not. Assuming they are big co’s. Ultimately I trust the board to extract value and the tech is looking more and more solid everyday, however the frustration is real 😆/😩
1
190
Wtf is this share price action. #avct Very frustrating. Given the progress, LTH’s should be sat on a comfortable profit having shouldered the risk. Really disappointing performance.
4
2
44
2,770
The market cap of #avct represents fantastic risk/reward. Which is both positive as I’m buying, but frustrating as I want to see value being attributed to the superb tech and ongoing de-risking.
9
1,031
Agree. I remember years ago discussing with shareholders how we had concerns FAP ‘could’ reduce during treatment putting the Med/Long term use of the platform at risk. Bizarrely no one ever suggested it would increase FAP…. And yet here we are. Fantastic! #avct
1
26
1,251
Does this mean that Avacta can administer AVA6103 to FAPlow expression and create a higher FAP environment which further compounds the resovoir affect?!? #avct
1
5
46
1,409
Transcriptomic analysis via RNA seq studies revealed that AVA6103 induced a coordinated inflammatory, wound-healing response, with an upregulation of pathways involved with damage repair, cell cycle arrest, and extracellular matrix (ECM) reorganisation’ 2/2
1
2
29
733
This is the best part of the RNS #avct ❤️🥇 incredible: ‘Tumor tissue studies from this experiment demonstrate that tumors treated with AVA6103 have increased FAP expression over time via immunohistochemistry, with recruitment of FAP+ fibroblasts over the course of treatment 1/2
2
10
1
60
4,059
Replying to @AndrewDigby3
Personally removed any hope of the SP moving significantly until p1 efficacy data is released followed by some form of deal. Anything else is a bonus. 👍🏻
1
3
161
*6000 feels ‘side of desk’ with 6103 performing (maybe rightly so). Potentially BP feel the same. *this time next year Rodney 👏🏻 Happy investor. SP is an opportunity, but must raise significantly through next year or unanswered commercial Q’s will be brought to a head 4/4 #avct
1
1
1
11
3,217
*6103 will take patient care to the next level. 6207 will be a whole new game, especially in hard to treat settings. *opportunity remains gigantic. More patience required. Board are in control & holding firm. BP will respect their IP & there resolve. 3/4 #avct
1
1
12
1,301
*A busy 8 weeks incoming. Gut feel is no commercial deal of value until 6103 efficacy H2. * ‘potential NASDAQ listing’ - #avct always commit & most often deliver. We’ve heard ‘potential NASDAQ’ for a while. I suspect it’s a Plan C for lack of deals. 2/4 #avct
2
1
11
1,318
My thoughts: *CC was excellent again. Discussing complexity with clarity & terminology that was absorbing for all. *confidence was high. 6103 readout being a close match to pre-clinical was the standout moment of the presentation for me. They must be seeing efficacy 1/4 #avct
1
3
28
2,068
Replying to @ZosoGraffiti
We will see… I sure hope so. I just feel like the tide is turning away from 6k all together, which I guess is positive because that’s due to the excitement around 6103. Fingers crossed they get it partnered soon to enable P2 & a much anticipated BP commercial deal
1
2
83
Replying to @massivefanNWO
No doubt it’s nice to see. I’m pleased they have done so & that does offer some confidence. But ‘tremendous confidence’? I’d be reserving that for II’s coming on board, raising at a premium, BP wanting a slice…. Etc.
1
1
4
182
Replying to @ZosoGraffiti
Agree, but I’m starting to think 6k will get superseded very quickly, therefore reducing profitability for a partner. This being my reasoning for 6k deals being v-low value.
2
3
133
‘This Fundraise demonstrates tremendous confidence in Avacta’ I find it hard to agree with that in honesty. A discounted raise on an already deflated SP doesn’t demonstrate tremendous confidence imo. I could agree if the raise was at a premium… #avct
4
1
27
2,415
6103 PK RNS followed by suspension & raise in order to value to markets appetite would have created the most value opportunity. Shame it wasn’t capitalised on. Anyway… life as an #avct SH goes on. Exciting times ahead remain on track ❤️
5
1,013
Slept on it & still disappointed. #avct Ben captures my thoughts well. A good post. fear for 6k is that nobody wants to deal at any decent value, as a next gen dox would wipe the floor (capping +pre|C +linker +dox) 🤔 Feels like an all or nothing crescendo on 6103 efficacy
3
12
2,004